These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30171809)

  • 1. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
    Mirzaev KB; Rytkin E; Ryzhikova KA; Grishina EA; Sozaeva ZA; Fedorinov DS; Konova OD; Giliarov MI; Belyakova GA; Andreev DA; Sychev DA
    Drug Metab Pers Ther; 2018 Sep; 33(3):109-118. PubMed ID: 30171809
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
    Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
    Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
    Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
    Liu X; Luo Y; Lai Y; Yao Y; Li J; Wang Y; Zheng SL; Xu J; Liu X
    J Genet; 2016 Jun; 95(2):231-7. PubMed ID: 27350664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays.
    Danielak D; Komosa A; Tomczak A; Graczyk-Szuster A; Lesiak M; Główka F; Karaźniewicz-Łada M
    Scand J Clin Lab Invest; 2017 May; 77(3):190-198. PubMed ID: 28276728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.
    Mirzaev KB; Samsonova KI; Potapov PP; Andreev DA; Grishina EA; Ryzhikova KA; Sychev DA
    Mol Biol Rep; 2019 Aug; 46(4):4195-4199. PubMed ID: 31102151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
    Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
    Tatarunas V; Jankauskiene L; Kupstyte N; Skipskis V; Gustiene O; Grybauskas P; Lesauskaite V
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):369-74. PubMed ID: 24418943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ; Shen CL; Wang BN; Huang XH; Hu ZL; Li J
    Gene; 2015 Mar; 558(2):200-7. PubMed ID: 25542807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419.
    Samardzic J; Bozina N; Skoric B; Ganoci L; Petricevic M; Krpan M; Pasalic M; Milicic D
    Int J Cardiol; 2015; 186():282-5. PubMed ID: 25828136
    [No Abstract]   [Full Text] [Related]  

  • 15. Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.
    Wójcik T; Szymkiewicz P; Wiśniewski J; Lebioda A; Jonkisz A; Gamian A; Kuliczkowski W; Ściborski K; Mysiak A; Protasiewicz M
    Adv Clin Exp Med; 2019 Dec; 28(12):1621-1626. PubMed ID: 31778598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
    Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
    Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clustering of ABCB1 and CYP2C19 Genetic Variants Predicts Risk of Major Bleeding and Thrombotic Events in Elderly Patients with Acute Coronary Syndrome Receiving Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
    Galeazzi R; Olivieri F; Spazzafumo L; Rose G; Montesanto A; Giovagnetti S; Cecchini S; Malatesta G; Di Pillo R; Antonicelli R
    Drugs Aging; 2018 Jul; 35(7):649-656. PubMed ID: 29936693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of CYP2C19 Polymorphism with Clopidogrel Resistance in Patients with Acute Coronary Syndrome in China.
    Su Q; Li J; Tang Z; Yang S; Xing G; Liu T; Peng H
    Med Sci Monit; 2019 Sep; 25():7138-7148. PubMed ID: 31543510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
    Bonello L; Camoin-Jau L; Mancini J; Bessereau J; Grosdidier C; Alessi MC; Ostorero M; Dignat-George F; Paganelli F
    Thromb Res; 2012 Jul; 130(1):70-4. PubMed ID: 22285300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
    Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
    J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.